Lexicon Pharmaceuticals Share Price Today

Citigroup raises Lexicon Pharmaceuticals price target to $3.4

Citigroup analyst Yigal Nochomovitz maintains a Buy rating on Lexicon Pharmaceuticals. Price target increased to $3.4 from the previous $3.1. No change in investment recommendation status.

Lexicon Pharma shares new sotagliflozin cardiovascular data at AHA

Sotagliflozin reduced arterial-like clot formation by **11.9%** and venous-like by **15.6%** in healthy adults. Empagliflozin reductions in clot formation did not reach statistical significance in the same crossover study. Sotagliflozin showed increased potency versus empagliflozin in reducing myocardial work in HCM tissue. Findings support dual SGLT1/2 inhibition mechanism ahead of SONATA-HCM topline results in Q1 2027.

Lexicon Pharmaceuticals Q3 loss narrows to $0.03; revenue beats estimates

Loss per share narrowed to $(0.03), beating consensus by 50%. Revenue of $11.3 million exceeded estimates but declined 20.67% YoY. SONATA-HCM enrollment complete; top-line data expected Q1 2027. Cash position strengthened to $183.2 million as of September 30, 2026.

Lexicon highlights sotagliflozin preclinical data on cardiac and thrombotic pathways

Preclinical studies show sotagliflozin improves cardiac structure and function in hypertrophic cardiomyopathy models. Dual SGLT1/SGLT2 inhibition reduces platelet activation and thrombus formation unlike selective SGLT2 inhibitors. Findings support further evaluation of sotagliflozin for HCM and potential cardiovascular risk reduction.

Lexicon Pharmaceuticals Q2FY26 Results: Net loss widens to $31.8 million

Net loss widened to $31.8 million in Q2 2026 from net income of $3.3 million in Q2 2025. Total revenue fell to $0.7 million from $28.9 million due to absence of prior-year licensing fees. R&D expenses increased to $17.4 million driven by Sonata HCM Phase 3 trial costs. Cash position improved to $190.6 million following a $100 million debt facility with Hercules Capital. Sotagliflozin HCM trial enrollment complete; Zynquista NDA resubmission targeted for Q4 2026.

Lexicon data shows sotagliflozin efficacy across blood pressure levels

Post hoc analysis of SOLOIST-WHF trial shows sotagliflozin efficacy across all baseline blood pressure levels. Patients with SBP <110 mmHg saw a hazard ratio of 0.56 for cardiovascular deaths and HF events. No increase in hypotension (p=0.34) or acute kidney injury (p=0.69) observed in treatment group. Results presented at ESC Congress 2026 and published in JACC: Heart Failure.